abiraterone
Interviews and expert commentary tagged “abiraterone” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer
SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of
12 February 2014
0:00
Audio Journal of Oncology
Responses to enzalutamide after prior abiraterone therapy in men with castration-resistant metastatic prostate cancer
SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri
11 February 2014
0:00
Audio Journal of Oncology
Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds
SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a
6 February 2014
0:00